Because of their substantial in vitro synergy, we conducted a dose-escalation study of cyclophosphamide (CP) added to 2-chloro-2′-deoxyadenosine (CdA) in patients with previously treated chronic lymphocytic leukemia and non-Hodgkin's lymphoma. CdA was given at a fixed dose (5.6 mg/m 2 /day) as a 2-h intravenous (i.v.) infusion, immediately followed by a 1-h i.v. infusion of CP, for 3 days. The initial daily CP dose was 200 mg/m 2 , and was escalated by 100 mg/m 2 increments in successive cohorts of three to six patients to determine the maximum-tolerated dose (MTD). Additional patients were included at the MTD to extend toxicity and response analysis. Twenty-six patients received 68 cycles of chemotherapy. The MTD of CP after CdA 5.6 mg/m 2 , was 300 mg/m 2 . Acute neutropenia was the dose-limiting toxicity of this regimen, which was otherwise well tolerated. Delivery of repeated cycles was not feasible in eight patients (31%) because of prolonged thrombocytopenia. Severe infections were seen in three of 68 cycles (4%). The overall response rate was 58% (15 of 26; 95% CI, 36-76%), with 15% complete responses and 42% partial responses. These data show the feasibility of the association of CdA with CP. Given the response rate observed, further studies of this regimen are warranted in untreated patients, in particular with chronic lymphocytic leukemia and with Waldenströ m macroglobulinemia. Leukemia (2000) 14, 1136-1142. Keywords: 2-chloro-2′-deoxyadenosine; cladribine; cyclophosphamide; chronic lymphocytic leukemia; non-Hodgkin's lymphoma
The purine nucleoside analogs 2-chloro-2′-deoxyadenosine (CdA) and fludarabine have established activity in the treatment of B cell chronic lymphocytic leukemia (CLL) and indolent non-Hodgkin's lymphoma (NHL). The hallmark of these compounds is their ability to kill both non-dividing and dividing cells via an apoptotic pathway. This may explain why they are effective in indolent lymphoproliferative disorders that usually have a low growth fraction rate and acquired resistance to apoptosis, together with the potential to accumulate active phosphorylated derivatives of purine analogs. 1 In B-CLL, purine analogs yield an unprecedented rate of complete remissions (CR) compared to alkylating agents at standard dose. 2, 3 CdA and fludarabine are also active in follicular lymphoma (FL), Waldenströ m macroglobulinemia (WM), mantle-cell lymphoma (MCL), and lymphoplasmacytic lymphoma. [4] [5] [6] [7] [8] To date however, these drugs have not been shown to confer a survival advantage over standard therapy. [9] [10] [11] In an attempt to increase the rate of CRs -as a step towards prolonged survival -one approach is to incorporate purine analogs into regimens that include agents such as chlorambuCorrespondence: E Van Den Neste, Hematology, Cliniques Universitaires Saint-Luc, 10, Av. Hippocrate, 1200 Brussels, Belgium; Fax: 32 2 764 8959 Received 17 November 1999; accepted 25 January 2000 cil (CLB) or cyclophosphamide (CP). This strategy relies on a variety of rationales including the individual activity of these agents in indolent lymphomas, their absence of significant extramedullary cross side-effects, and their synergistic toxicity in vitro. [12] [13] [14] This latter interaction is thought to result from the inhibition of DNA repair by purine analogs, leading to enhanced retention of alkylating agents-induced DNA crosslinks. 12, [15] [16] [17] [18] [19] [20] Finally, the persistence of sensitivity to purine analogs in patients pretreated with alkylating agents, in vitro as well as clinically, suggests non-cross resistance between these compounds. 12, 21 The clinical synergy with alkylating agents, as expected from the in vitro studies, has already been shown with fludarabine combined with CP at various dosages, an active -but potentially toxic -regimen in patients with lymphoproliferative disorders. 2, [22] [23] [24] [25] The combination of CdA or fludarabine with CLB is active, but associated with dose-dependent infections and cumulative myelotoxicity. [26] [27] [28] The combination of low-dose CdA with CP was shown to be feasible and active in patients with indolent lymphomas. 29 These data suggest that the association of purine analogs with CP is promising although the reported schedules of administration are variable and, hence, not hitherto standardized despite the potential hazards of severe toxicity.
The present phase I/II study was designed to identify the maximum-tolerated dose (MTD) and the activity of dose-reduced CdA in combination with escalating doses of intravenous (i.v.) CP in relapsed or refractory patients with lymphoproliferative disorders.
Patients and methods

Patient selection
Patients with relapsing and/or refractory B-CLL or indolent NHL were eligible. Other eligibility criteria were: Eastern Cooperative Oncology Group performance status р2; life expectancy у3 months; age у18 years; appropriate contraception; no prior chemo-, immuno-or radiotherapy for at least 4 weeks before entry; complete recovery from toxic effects of previous antitumor therapy; absence of active infection; satisfactory hematologic parameters (neutrophil count Ͼ1.0 × 10 9 /l, platelet count Ͼ50 × 10 9 /l) unless due to disease infiltration; absence of autoimmune cytopenia; AST and ALT within 2.5 times the normal upper limit; bilirubin and creatinine levels within the normal range. Written informed consent was obtained from all the patients. The hospital ethics committees of the participating institutions approved the protocol.
Treatment plan, dose escalation and toxicity evaluation
CdA was synthesized and supplied by Pr L Ghosez (Laboratory of Organic Chemistry, Université Catholique de Louvain, Belgium) as a 1 mg/ml pyrogen-free CdA solution in 0.9% sodium chloride. CdA 5.6 mg/m 2 was diluted in 100 ml 0.9% sodium chloride and given as a 2-h i.v. infusion for 3 days, every 28 days. To maximize the opportunity for synergism, CP was given immediately after the end of each CdA infusion, as a 1-h i.v. infusion, for 3 days. The dose of CdA was fixed, whereas the dose of CP was to be raised by increments of 100 mg/m 2 . The initial CP dose was 200 mg/m 2 . Patients were treated as outpatients and attended the clinic once weekly, with a blood count and other tests carried out as appropriate. Treatment was withheld until the platelet count had achieved at least 75% of its pretreatment values or was greater than 100 × 10 9 /l, and when the neutrophil count had reached at least pretreatment values or was greater than 1.0 × 10 9 /l. The planned number of courses was four. However, in responding patients, it was allowed to extend the treatment to six courses depending on the tolerance.
All patients received prophylaxis against Pneumocystis carinii pneumonia (PCP) with cotrimoxazole 960 mg p.o. twice daily on 2 days/week. Oral norfloxacin 800 mg/day and fluconazole 50 mg/day were allowed in case of neutropenia. Prophylactic use of colony-stimulating factors was not allowed at the first cycle. Blood products were irradiated.
Toxicity was evaluated according to the NCI common cytotoxicity criteria. Dose-limiting toxicity (DLT) was defined as a grade 4 neutropenia lasting longer than 7 days, a grade 4 thrombocytopenia, a neutropenic fever, or a grade Ͼ2 nonhematological toxicity except for nausea, vomiting and alopecia. Toxicity-related treatment delays longer than 2 weeks, such as after prolonged cytopenia, were also considered as DLT. Grade Ͼ2 nausea/vomiting or diarrhea was regarded as DLT only if observed despite curative treatment. Dose escalation occurred in cohorts of a minimum of three patients and was halted if a DLT was encountered in two or more of these three patients. If only one patient developed DLT, up to five additional patients were entered at that particular dose level. The MTD was defined as the dose level immediately under the level at which у one-third of patients experienced DLT during the first course. DLTs that occurred during subsequent cycles of chemotherapy were recorded, but did not affect the dose-escalation decision. After definition of the MTD, the study was further expanded at that dose level. Patients experiencing severe neutropenia were allowed to continue on the study with granulocyte colony-stimulating factor (G-CSF) support, and/or CP dose reduction (of one dose level). Late complications were any events arising after recovery from the last cycle until the most recent follow-up.
Response evaluation
Response was assessed 4 weeks after the second course, at the end of treatment and every 3 months until progression. Response duration was calculated from the first day of the response assessment. Response criteria for CLL were according to the recommendations of the NCI-CLL study group. 30 In lymphoma, response was evaluated using standard criteria. 31 In WM, CR was defined as the disappearance of monoclonal IgM and all other evidence of disease. PR was defined as a Ͼ50% decrease of monoclonal IgM for at least 2 months, Leukemia accompanied by a Ͼ50% reduction of tumor infiltrate at all involved sites.
Results
Patient characteristics
From October 1997 to December 1998, 26 patients received treatment with CdA and CP. Patient characteristics are listed in Table 1 . Median interval between diagnosis and study inclusion was 5.1 years (range 0.4-18.8 years). Fifty-four percent of the patients were refractory to their last treatment and 50% (13 patients; 11 with CLL, two with WM) had previously received a purine analog alone. The median interval between last administration of a purine analog in monotherapy and study entry was 17 months (range 8-57 months). The median number of prior courses of CdA and fludarabine was six (range 4-10 courses) and six (range 6-8 courses), respectively. The median age of CLL patients was 66. The Binet stage was A in one, B in seven, and C in five of them. Ten of them had karyotypic abnormalities at inclusion. One patient with CLL had a positive direct antiglobulin test (DAT) at inclusion. Among the 10 patients with a diagnosis of NHL, nine were in stage IV, and one in stage II, according to the Ann Arbor staging. All lymphomas were of B cell origin. Median LDH level of patients with NHL was 401 U/l (range 293-1415 U/l).
A total of 68 treatment courses with CdA and CP were given to the 26 patients through three CP dose levels. The median number of courses administered at dose level 1, 2/2′, and 3, was two (range 2-4 courses), two (range 2-5 courses), and one (range 1-3 courses), respectively. Eight patients (31%) concluded the planned four courses of chemotherapy. 
Dose escalation and determination of first-cycle MTDs and DLTs
All patients were assessable for toxicity. The first four patients were treated with 200 mg/m 2 CP and all completed the first cycle without DLT (Table 2 ). At the second dose level (CP 300 mg/m 2 ), no DLT occurred after the first cycle in five patients. Accordingly, three patients were treated at dose level 3 (CP 400 mg/m 2 ) with two patients experiencing DLT, namely, uncomplicated prolonged grade 4 neutropenia in one patient, and prolonged grade 4 neutropenia together with grade 4 thrombocytopenia and grade 3 infection in the other. By protocol definition, dose-escalation was halted and dose level 2 was defined as the MTD. Fourteen additional patients were included at the MTD (dose level 2′). DLTs were seen in five of them, including grade 4 neutropenia lasting Ͼ7 days (n = 3), pulmonary aspergillosis (n = 1), and persisting grade 3 thrombocytopenia (n = 1). Among the 19 patients treated at dose level 2 (n = 5) or 2′ (n = 14), with CP at 300 mg/m 2 , five (26%) experienced a DLT after the first course.
Toxicity during all cycles of treatment
The cumulative prevalence of DLT and significant hematological toxicities are listed in Tables 3 and 4 , respectively. Neutropenia was the most common side-effect, with 14 (21% of cycles) episodes of grade 3, and 29 (43%) of grade 4. Among the 20 patients who received more than one cycle, three were removed because of protracted neutropenia, whereas no treatment delays were observed for the same reason in the others. A cumulative effect on neutropenia was hence not clearly Table 3 Cumulative observed, taking into account the fact that 12 cycles were supported by G-CSF and that three patients included at level 2′, and one included at level 3, had a reduction in their dosage of CP after the first cycle. Grade 4 neutropenia was abrogated in nine of the 12 cycles supported by G-CSF. Neutropenic fever was observed in 8% of the patients (two of 26) and 3% of the cycles (two of 68). Eight patients (31%) required discontinuation of therapy because of persistent grade 3 thrombocytopenia: two after one course, five after two to three courses, and one after four. Two had been treated at dose level 3, and six at dose level 2/2′. Four of them had received a purine analog in monotherapy prior to study inclusion. It is worth noting that, at study entry, 11 patients had grade 1 to 3 thrombocytopenia. No patient required platelet transfusions. Grade 3/4 anemia was noted in four patients. However, half of the patients entered the study with some degree of anemia. There was no documentation of positivation of DAT. Nevertheless, two patients with CLL developed moderate DAT-negative hemolytic anemia. No specific therapy was required in one.
The other responded to oral steroids. Three episodes of grade 3/4 infection were seen in three patients: pulmonary aspergillosis (n = 2), concomitant gramnegative and streptococcal pneumonia (n = 1). Episodes of grade 1/2 infection were noted, including upper respiratory tract infections (n = 6), oral herpes simplex (n = 3), dermatomal herpes zoster (n = 2), skin infections (n = 2), Clostridium difficile colitis (n = 1), and oral candidiasis (n = 1).
Among nonhematologic toxicities, mild and easily controllable nausea and vomiting were the most prominent. Grade 3/4 vomiting was observed in only one patient. One patient with abdominal FL developed bullous pemphigoid after his fourth course, concomitantly to disease progression. Severe asthenia was not observed outside disease progression.
Late-occurring complications were observed. One patient with CLL, who was on steroids for hemolysis, developed PCP 4 months after study withdrawal. One patient had herpes zoster and one a digestive infection with Entamoeba histolytica. Two patients developed lung tumors (one adenocarcinoma and one squamous cell carcinoma) 16 and 6 months after inclusion, respectively. Both were smokers. T-lymphocyte interstitial pneumonia occurred 7 months after inclusion in a patient with CLL. Pneumonia fully responded to corticosteroids. One patient with progressive CLL and positive DAT before inclusion developed hemolysis 4 months after end of study.
Globally, 12 patients (46%) were removed due to toxicities: lasting thrombocytopenia and/or neutropenia in 10 (concomitantly to hemolysis in two, disease progression in one and pulmonary infection in one), pulmonary aspergillosis with disease progression in one and bullous pemphigoid in one patient. The remainder were removed because of disease progression (four patients) or consent withdrawal (two patients). Five patients died after withdrawal: four from progression and one from a lung carcinoma. 
Antineoplastic activity, response duration and survival
A CR was achieved in four (15%), and a PR in 11 (42%) of the 26 patients ( Eight of the 13 patients with CLL responded, including one immunological CR, one nodular PR, and six PRs. Two patients with NHL achieved a CR and three a PR. Two patients with WM responded (one CR and one PR, respectively). The response rate at the recommended dose level (2/2′) was 68% (13 responders among the 19 patients included at that dose level).
Among the purine analog-pretreated responders, three patients with CLL achieved a better response than after the single CdA or fludarabine. Cases 1 and 20 went into PR after treatment with CdA and CP, whereas they had only stable disease after monotherapy with CdA or fludarabine, respectively. Case 5 had achieved a 6-month duration PR after CdA. A lasting (19+ months) nodular PR was obtained after four cycles Table 5 Responder characteristics (n = In PR after CdA given in first line, stable disease after rechallenge with CdA, refractoriness to CLB. b Stable disease after fludarabine. CHOP, cyclophosphamide-doxorubicin-vincristine-prednisone; miniCHVP, cyclophosphamide-low-dose doxorubicin-VP16-prednisone; HDCP, high dose cyclophosphamide; fluda, fludarabine; autoG, autografting; INF␣, interferon ␣2b; SD, stable disease; PD, progressive disease; CR, complete remission; NA, non applicable; nPR, nodular partial remission.
Leukemia of the study drugs. Three of the non-responders with CLL received only one cycle because of toxicity. Table 6 shows the non-responder characteristics. Compared to the responders, these patients tended to be more heavily pretreated since they had all received an anthracyclin and/or a purine analog prior to inclusion. In addition, they were given a significantly lower number (P Ͻ 0.05) of cycles of CdA and CP (median: 2, range 1-4 cycles), compared to the responders (median: 3, range 1-5 cycles).
Discussion
Our results demonstrate the feasibility of combined CdA and CP in the treatment of B-CLL or indolent NHL. Based on the toxicities of the first cycle, the DLT was neutropenia. Neutropenia rarely translated into fever or severe infection. Thrombocytopenia did not lead to bleeding but was dose-limiting because of slow recovery in 31% of the patients. This suggests that the incidence of thrombocytopenia would be most likely unacceptable with further dose escalation, even if the systematic use of G-CSF from the first course might allow higher doses than in our recommended level with respect to neutro- Table 6 Non-responder characteristics (n = penia. A potential limitation of this study is inclusion of patients pretreated with a purine analog. This may have affected dose escalation, because of impaired medullar reserve. The investigational design of our study led us to include only CLL and WM patients with poor prognosis features such as relapse after purine analog and/or refractoriness to CLB. Care was taken to include only patients who had a relatively long period off therapy with purine analogs (no patients refractory to purine analogs included). It is worth noting that dose limiting thrombocytopenia was observed equally in patients previously treated with CdA or fludarabine, as well as in those who had never received these drugs prior to study entry. The toxicity encountered in this trial has to be viewed in the context of the treated patients. Poor medullar tolerance has been highlighted as a major cause of failure after CdA therapy, especially in patients who are rechallenged with a purine analog. 3, 23, [32] [33] [34] [35] [36] Marrow suppression was also a limiting factor in trials of purine analogs combined with CLB or CP in indolent lymphomas. With the association of fludarabine and CLB in pretreated patients, although previously unexposed to fludarabine, the DLT was myelosuppression, with cumulative patterns of platelet suppression. 26 Similarly, in the study by Weiss et al 27 on the same association, grade 3 to 4 thrombocytopenia was observed in 73% of the patients, leading to a relatively low dose-intensive regimen and a low response rate. Again, attempts to repeat the cycles resulted in excessive myelosuppression after the combination of low-dose CdA with CLB. 28 Laurencet et al 29 reported a study of low-dose subcutaneous CdA (0.1 mg/kg/day for 3 days, up to 5 days in tolerating patients) with 500 mg/m 2 CP. Incidence of cumulative myelosuppression and infection was acceptable, considering that 12 of the 19 included patients had not received prior chemotherapy and that pretreatment in the others was moderate (no prior purine analogs). Compared to the present study, dose-intensity of their 3-day schedule was inferior for CdA, as well as for CP. Weber et al 37 showed the feasibility of subcutaneous CdA with oral CP in newly diagnosed patients with WM. Toxicity mainly consisted of neutropenia. Significant problems with cytopenia have been reported after the combination of fludarabine with CP as salvage treatment. Their incidence may decrease in untreated patients, or with dose reduction in CP or use of G-CSF. [22] [23] [24] [38] [39] [40] These data suggest that the toxicities seen in our study were not in excess compared to the other combinations of purine analogs with alkylating agents, also considering that single drug CdA may by itself cause significant cytopenia and infections in pretreated patients. [41] [42] [43] It remains to be demonstrated that CdA, either alone or combined with immunosuppressive agents such as CP, may raise the risk of secondary neoplasms. 44 The response rate was encouraging in CLL patients, notably when considering their characteristics at study entry, and of the order of what has been reported with other combinations of purine analogs. 2, 23, 29, 40 From this study, it is impossible to conclude that the combination is more active than the single agent. However, achievement of better responses after CdA and CP than after CdA or fludarabine alone in several patients, together with the fact that significant responses were seen in patients refractory to alkylating agents, suggests validation of the mechanistic synergism between CdA and CP.
In summary, the combination of CdA with CP was generally well tolerated with cytopenia being the DLT. The response rates achieved in CLL and WM broaden the range of therapeutic options in the salvage treatment of these diseases, potentially even after purine analogs in monotherapy. In keeping with a few other reports, the risk of cytopenia advocates the use of growth factors. 23, 38 Prior in vitro confirmation of the sensitivity to CdA and CP could help to select within patients with expected poor BM reserve. Given the evidence of a better tolerance to purine analogs in newly diagnosed patients, we are planning to test our schedule, at our recommended dose level, in untreated patients with CLL or WM, with particular emphasis on the risks of cumulative thrombocytopenia, difficulties in harvesting stem cells, hazards of secondary neoplasms and autoimmune complications.
